NCT00367224已完成不适用
Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to determine if vitiligo patients develop tolerance to ultraviolet light therapy, a type of treatment available for vitiligo.
详细描述
Patients with vitiligo received 6-9 ultraviolet B treatments, 2 to 3 times weekly. Minimal erythema dose (MED) testing was done at baseline and after all treatments; the percent change in MED was analysed as a measure of photoadaptation. The percent decrease in cyclobutane pyrimidine dimers (CPDs) over 24 hours after a single exposure of 1 MED was analysed on vitiliginous and normal skin.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For inclusion, the subject must:
- •Be at least 18 years old
- •Be otherwise healthy
- •Have a diagnosis of vitiligo affecting > 5% body surface area (BSA)
- •Have two depigmented lesions on opposite sides of the body that can be biopsied at the end of TARGETED UVB PHOTOTHERAPY treatment
- •Agree to abide by the Investigator's guidelines regarding photosensitizing drugs
- •Have a negative pregnancy test at baseline if female of childbearing potential
- •Be able to understand the requirements of the study, the risks involved, and is able to sign the informed consent form
- •Agree to follow and undergo all study-related procedures
排除标准
- •Subjects will be excluded if any of the following apply:
- •Women who are lactating, pregnant, or planning to become pregnant
- •Patients with a recent history of serious systemic disease
- •Patients with a known history of photosensitivity
- •Concomitant use of systemic or topical treatments for vitiligo. Patients must discontinue PUVA or oral corticosteroid therapy for 4 weeks prior to the start of any treatment. If a patient is taking any vitamins or dietary supplements, the patient must discontinue them for the duration of the study. Topical therapy such as corticosteroids, topical immunomodulators (e.g., Protopic or Elidel), vitamin D derivatives (e.g., Dovonex), or UVB phototherapy must be discontinued for 2 weeks prior to the start of study treatment.
- •Patients diagnosed to be immunosuppressed for any reason (e.g., HIV infection, lupus, cancer, organ transplant, or chronic use of oral immunosuppressive agents).
- •Any reason the investigator feels the patient should not participate in the study
研究者
Iltefat Hamzavi
Dermatologist
Henry Ford Health System
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic SubjectsAcneNCT05168397Pierre Fabre Dermo Cosmetique45
已完成
不适用
Deliberate Ultraviolet Light Exposure to Get a Tan by Young Adult Sexual Minority MalesSun SensitivityNCT04404907Northwestern University537
已完成
不适用
The Effect of UVB Phototherapy With Microneedling and Circled Needing in Vitiligo PatientsBrief Description of Focus of Study InsteadNCT03718962Shin Kong Wu Ho-Su Memorial Hospital9
已完成
不适用
Tolerance and Mode of Administration of Cyto-selective Cryotherapy Treatments in Face Brown Spots: Proof of ConceptSolar LentigoNCT05203263Cryonove Pharma23
Unknown
早期 1 期
Effects of Camouflage on the Life Quality of Patients With VitiligoQuality of LifeNCT03540966Xijing Hospital400